ELP1 rs121907994: Understanding the Familial Dysautonomia Variant
The rs121907994 variant in the ELP1 gene is a well-documented splice site mutation known as the primary founder mutation for familial dysautonomia. It is an autosomal recessive condition that occurs almost exclusively in individuals of Ashkenazi Jewish descent.
What each genotype means
Non-carrier
You carry two reference copies of the gene and do not carry the c.2204+6T>C founder splice variant. Research indicates you are not an asymptomatic carrier of this specific familial dysautonomia mutation. This result does not rule out very rare or non-founder variants in the ELP1 (IKBKAP) gene.
Carried by approximately 97% of individuals of Ashkenazi Jewish descent and over 99.9% of individuals from other global populations.
Familial dysautonomia carrier
You carry one copy of the c.2204+6T>C splice variant (historically designated IVS20+6T>C) and one normal copy. Because familial dysautonomia is an autosomal recessive condition, single-copy carriers typically do not show neurological symptoms. However, you have a 50% chance of passing this variant to biological offspring, which has reproductive implications if a partner is also a carrier.
Found in approximately 1 in 30 to 1 in 32 individuals of Ashkenazi Jewish ancestry, but is exceedingly rare in other populations.
High risk for familial dysautonomia
You have two copies of the c.2204+6T>C pathogenic splice variant in the ELP1 (IKBKAP) gene. In published research, this homozygous genotype causes aberrant exon skipping and is associated with familial dysautonomia, an autosomal recessive sensory and autonomic neuropathy. Individuals with this genotype generally undergo comprehensive clinical and genetic evaluation.
Observed in roughly 1 in 3,600 live births in Ashkenazi Jewish populations and is extremely rare outside this group.
What is the rs121907994 Variant?
The variant rs121907994, often referred to in scientific literature as c.2204+6T>C or IVS20+6T>C, is a specific change in the DNA sequence of the ELP1 gene. Located at the 5' splice site of intron 20, this mutation involves a transition from a thymine (T) to a cytosine (C) base. This specific location is critical because it acts as a signal for the cellular machinery to correctly piece together, or splice, the messenger RNA (mRNA) that provides instructions for building the ELP1 protein. When this signal is altered, the splicing process is disrupted, often leading to the exclusion of exon 20. This results in the production of a truncated and largely nonfunctional version of the ELP1 protein, which is essential for the development and maintenance of various cell types, particularly within the nervous system.
The Role of the ELP1 Gene
The ELP1 gene, formerly known as IKBKAP, provides the genetic blueprint for the ELP1 protein, which is a key component of the elongator complex. This complex is involved in several fundamental cellular processes, including the regulation of gene expression and the modification of proteins. Research indicates that the ELP1 protein is expressed in many tissues throughout the body, with particularly high levels of activity in the brain and other parts of the nervous system. Because the protein is vital for neuronal development and survival, disruptions in its production can have profound effects on the autonomic and sensory nervous systems. In the context of familial dysautonomia, the reduced levels of functional ELP1 protein are believed to impair the growth and survival of nerve cells, leading to the characteristic symptoms of the condition.
Research and Clinical Associations
The rs121907994 variant is recognized as the major founder mutation for familial dysautonomia (FD), a rare sensory and autonomic neuropathy. Scientific evidence strongly associates this variant with the disease, as it accounts for more than 99% of the pathogenic alleles identified in individuals with FD. The condition follows an autosomal recessive inheritance pattern, meaning that an individual must typically inherit two copies of the mutation—one from each parent—to manifest the clinical symptoms of the disorder. While the association between this variant and FD is well-established, the severity of the condition can vary, and researchers continue to study how the residual production of functional ELP1 protein might influence the clinical presentation. It is important to note that this information is for educational purposes and does not constitute a medical diagnosis.
Population Frequency and Carrier Status
This variant is primarily observed in individuals of Ashkenazi Jewish descent, where it is considered a founder mutation. Population studies have consistently reported a carrier frequency of approximately 1 in 30 to 1 in 36 within this specific ethnic group. Because the condition is autosomal recessive, carriers—who possess only one copy of the mutation—typically do not exhibit the signs or symptoms of familial dysautonomia. The variant is extremely rare in the general population outside of this ancestry. Genetic screening programs for individuals of Ashkenazi Jewish descent often include testing for this specific mutation to provide prospective parents with information regarding their carrier status and the potential risk of passing the condition to their children.
What This Information Means for You
Understanding your genetic status regarding rs121907994 can provide insight into your carrier status, particularly if you are of Ashkenazi Jewish ancestry. If you have received results indicating you are a carrier, it simply means you have one copy of the variant and are not expected to develop familial dysautonomia yourself. However, if both parents are carriers, there is a statistical possibility of having a child affected by the condition. This information is intended for educational purposes and should not be used to make personal health decisions. If you have concerns about your genetic results or family history, it is essential to consult with a qualified genetic counselor or a healthcare professional who can provide personalized guidance and discuss appropriate testing or family planning options.
How common is this variant?
The rs121907994 variant is a founder mutation in the Ashkenazi Jewish population, with a carrier frequency estimated at approximately 1 in 30 to 1 in 36.
Frequently asked questions
What is familial dysautonomia?
Familial dysautonomia is a rare, inherited disorder that affects the development and survival of sensory and autonomic neurons. It leads to difficulties with involuntary bodily functions, such as blood pressure regulation, temperature control, and digestion.
If I am a carrier of the ELP1 mutation, will I get sick?
No, carriers of the ELP1 mutation typically do not show signs or symptoms of familial dysautonomia. The condition is autosomal recessive, meaning it generally only affects individuals who inherit two copies of the mutation.
Should I get tested for the ELP1 mutation?
Genetic testing for the ELP1 mutation is often recommended for individuals of Ashkenazi Jewish descent who are planning a family. You should discuss the benefits and implications of this testing with a genetic counselor or your primary care physician.
Is there a cure for familial dysautonomia?
Currently, there is no cure for familial dysautonomia. Treatment focuses on managing the symptoms and providing supportive care to improve the quality of life for affected individuals.
Sources & further reading
Educational information only, last refreshed 10/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121907994?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29